"People's Daily" praised the birth of the first test tube baby conceived through single sperm sequencing technology in Northeast China
According to a report from the People’s Daily on September 2, the team of Shengjing Hospital, Tan Jichun recently applied single sperm sequencing technology for the first time to block the transmission of achondroplasia to help a couple successfully give birth to a healthy baby, this is the first test tube baby born in Northeast China using single-sperm sequencing technology.
For patients with the achondroplasia and heterozygous mutations of FGFR3 gene c.1138G>A, which is a, male patients with new mutations who cannot be subjected to routine linkage analysis, Professor Tan Jichun applied single sperm sequencing technology to perform preimplantation genetics testing on the patient’s embryo. In the end, the professor selected a healthy embryo for implantation. The subsequent amniocentesis results showed that the fetus had normal chromosomes and did not carry the c.1138G>A mutation. The patient's wife given birth to a healthy baby at 39 weeks.
Fetal amniotic fluid samples are tested for a gene locus, which indicates that the fetus does not carry the FGFR3 gene c.1138G>A mutation and baby is not a patient with dwarfism.
PGT (pre-implantation genetic testing, commonly known as "third-generation test tube baby") refers to the process of transferring normal embryos into the mother's uterus through molecular testing of cells after embryo biopsy. For couples suffering from a single-gene genetic disease or carriers of pathogenic gene, they are at increased risk of giving birth to offspring of certain genetic disease, so they can choose PGT to assist in pregnancy. In order to improve the accuracy of preimplantation genetic testing, it is usually necessary to perform family linkage analysis, to perform haplotype linkage analysis on the basis of both spouses and their previous children who born with a genetic disease. However, the prerequisite is to have a proband or a complete genealogy to construct a haplotype, and then complete the PGT test and block the familial transmission of genetic diseases.
At present, there are 50 million infertility patients in China, and nearly 10 million of them need assisted reproductive technology to achieve birth. In February of this year, the PGT-A testing kit independently developed by Basecare was approved by the National Medical Products Administration (Approval No.: 20203400181), marking China's per-implantation genetic testing technology is licensed and entered the medical device supervision era. Suzhou Basecare Medical Co., Ltd. is a leading enterprise in the reproductive health market segment. Since its establishment in 2010, it has been focusing on the application and research of genetic technology in the field of fertility, striving to overcome these clinical reproductive problems, and constructing a full reproductive cycle around embryo detection, and has formed a product testing system for pre-pregnancy, prenatal and newborns.
As the clinical problems of assisted reproduction have been successfully overcome, more and more families will benefit from this technology, and more and more healthy babies will born using this technology.